Anavex Life Sciences Corp (AVXL)

[XenaLives]

Lets get down to specifics here - There will only be five companies, here are the PRs. One mentions that the CFO will be arranging individual face time with investors. So it seems that Missling will be talking to money people. The question remains, is Mizuho pulling together investors for other shelf offerings? It is also not unlikely that Takeda will attend given the topic.

I still believe that Mizuho is greasing the skids for drugs that are needed in Japan and Japanese investment. Anavex is in very good company here, this is not a cattle call.

Mizuho calls it "Mizuho Therapeutics Day"
https://www.mizuhoamericas.com/who-we-are/events

Anavex

Anavex to Participate in Mizuho Therapeutics Conference

Conference to Feature Companies with Focus on Alzheimer’s, Parkinson’s and other Neurological Diseases

NEW YORK, NY – September 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in Mizuho Therapeutics Conference on Wednesday, September 21, 2016. The conference will be held at the Langham Hotel in Boston, Massachusetts.

Investors interested in attending may contact the conference organizers or Anavex Investor Relations.

Forward Pharma
Emphasis mine:

Forward Pharma CFO to Participate in Three Investor Conferences in September

COPENHAGEN, Denmark, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences:

Wells Fargo Securities Healthcare Conference to be held at the Westin Boston Waterfront in Boston, Massachusetts. Mr. Sendek will host one-on-one meetings on Wednesday, September 7th.
Morgan Stanley Healthcare Conference to be held at the Grand Hyatt in New York, New York. Mr. Sendek will present on Monday, September 12th at 4:50 PM EDT.
Mizuho Therapeutics Conference to be held at the Langham Hotel in Boston, Massachusetts. Mr. Sendek will host one-on-one meetings on Wednesday, September 21st.

Investors and other interested parties may access a live audio webcast of our conference presentation by visiting the investor page on the Company’s website (www.forward-pharma.com). The audio replay will be available via our website for 90 days following the presentation.

About Forward Pharma:
Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. Since our founding in 2005, we have worked to advance unique formulations of DMF, which is an immune modulator, as a therapeutic agent to improve the health and well-being of patients with immune disorders including multiple sclerosis. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose.

Our principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market (FWP). For more information about the Company’s products and developments, please visit our web site at http://www.forward-pharma.com.

https://globenewswire.com/news-release/2016/09/06/869656/0/en/Forward-Pharma-CFO-to-Participate-in-Three-Investor-Conferences-in-September.html


Flex Pharma

Calls it a Neuro Focus conference.

Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it will present a corporate overview at the following upcoming investor conferences in September:

The BioCentury NewsMakers Conference on September 9, 2016 at 11:30 a.m. in New York, NY;
The Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016 at 9:35 a.m. in New York, NY;
The Mizuho Neuro-Focus Therapeutics Conference on September 21, 2016 in Boston, MA.

A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma’s website for 2 weeks following each presentation.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

Astra Zeneca -

Couldn't find a PR, just on their calendar.
https://www.astrazeneca.com/investor-relations.html

Innotec

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer, and Claudine Prowse, PhD, Vice President, Strategy and IRO, are scheduled to participate at the following investor conferences:

Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016 in New York City
Mizuho Securities Therapeutics Conference on September 21, 2016 in Boston, MA

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com. The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.

http://www.businesswire.com/news/home/20160906005184/en/Inotek-Pharmaceuticals-Announces-Participation-Upcoming-Investor-Conferences